CASE REPORT

Diurnal enuresis developing in association with risperidone and aripiprazole use in a child with autism spectrum disorder: a case report

Hamza Ayaydin and Şermin Bilgen Ulgar

Department of Child and Adolescent Psychiatry, Faculty of Medicine, Harran University, Şanlıurfa, Turkey

ABSTRACT

Autism spectrum disorder (ASD) is a complex heterogeneous neurodevelopmental disorder. Risperidone and Aripiprazole appear to be effective in associated behavioural problems with ASDs, including irritability, aggressiveness, hyperactivity, self-injurious behaviour, and stereotypies [1,2]. Diurnal enuresis is defined as involuntary daytime voiding of urine. Enuresis is a side-effect that adversely affects treatment compliance and quality of life for children and their carers. Various psychotropic agents have been reported to cause nocturnal enuresis. In order of prevalence, these include clozapine, olanzapine, quetiapine, and risperidone [3]. Younger age may also add a greater risk for enuresis [4]. In our case, new-onset diurnal enuresis was observed as a side effect after risperidone use. New-onset diurnal enuresis improved when risperidone was stopped, but recommenced when aripiprazole was added to treatment. However, all symptoms of enuresis resolved when the aripiprazole dosage was reduced. In contrast to some reports in which aripiprazole was used in the treatment of enuresis, our case is different in that it led to diurnal enuresis.

Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin type 1A (5HT1A) receptors, and as an antagonist at serotonin type 2A (5HT2A) receptors [6].

New-onset diurnal enuresis improved when risperidone was stopped, but recommenced when aripiprazole was added to treatment. However, all symptoms of enuresis resolved when the aripiprazole dosage was reduced. In contrast to the therapeutic effect of aripiprazole in the treatment of enuresis developing in association with clozapine use, in our case enuresis developed when the aripiprazole dosage was increased [5]. In contrast to some reports in which aripiprazole was used in the treatment of enuresis [5], our case is different in that it led to diurnal enuresis. Then enuresis subsequently resolved, with no impairment of improvement in behavioural problems, following a mild dose reduction. To the best of our knowledge, ours is the first case that risperidone and aripiprazole-induced diurnal enuresis in a preadolescent with autistic disorder.

Case presentation

A 5-year-old female was referred to our outpatient clinic for her aggressiveness, severe temper tantrums, self-injurious behaviours, stereotypes, and hyperactivity. She was diagnosed with ASD due to his severe impairment in language development and social-emotional reciprocity and repetitive behaviours and restricted interests. Because of her behavioural problems and repetitive behaviours, risperidone was initiated at 0.25 mg/day and then the dose was increased to 0.5 mg/day. Her behavioural problems improved partially, but within the second week of risperidone treatment she developed new-onset diurnal enuresis. Her medical history and workup, including blood biochemistry tests, fasting glucose, ultrasonography, urinalysis, electroencephalography and neurological examination, were all normal. She had urinary bladder control at three years of age, and she and her family had no previous history of urinary incontinence. Because her mother requested the discontinu-
ation of risperidone due to the adverse effect on the fourth week of treatment, we decided to switch to aripiprazole. Enuresis ceased rapidly during the first week of risperidone discontinuation. Because of her behavioural problems, aripiprazole was initiated at 2 mg/day and gradually titrated up to 4 mg/day over two weeks. Within the second week of treatment, she developed diurnal enuresis again. Her medical workup, including blood biochemistry tests, fasting glucose, ultrasonography, urinalysis, electroencephalography and neurological examination, was normal. On the 4th week of treatment, her parents reduced the dose of aripiprazole used from 4 mg/day to 3.5 mg/day due to persistence of enuresis. The patient’s enuresis resolved with no adverse effect on the improvement in her behavioural problems within one week after dose reduction.

**Discussion**

We report a female patient with ASD developing new-onset diurnal enuresis following both risperidone and aripiprazole use. Enuresis resolved entirely following a slight reduction in aripiprazole dosage from 4 mg/day to 3.5 mg/day, while the effectiveness of treatment was maintained.

Although it is difficult to state risperidone or aripiprazole definitively as the causes of new-onset diurnal enuresis in the case, the chronological process and dramatic response to risperidone discontinuation and aripiprazole dose reduction in the absence of an identifiable medical cause are suggestive of the causal effect. Several reports have described enuresis developing in association with antipsychotics [3,5,7,8]. In some reports, enuresis resolved spontaneously during the therapeutic process, while in other reports, enuresis improved with the addition of another antipsychotic (such as aripiprazole) [5]. Other reports described no recurrence of enuresis when one drug was stopped and the patient started on another antipsychotic [7]. In our case, risperidone was stopped because it caused enuresis, but enuresis recurred when the patient was started on aripiprazole. Two consecutive antipsychotics causing enuresis, and that enuresis improving following a slight aripiprazole dose reduction of 0.5 mg/day, and the effectiveness of treatment being maintained, suggested that the drug dosage should be reduced to the lowest level needed to maintain clinical effectiveness in order to resolve the enuresis, before adding another drug or stopping one drug and immediately switching to another.

While the pathophysiology of antipsychotic-induced enuresis remains unclear, a number of mechanisms have been described, including: (1) reduced dopamine transmission in the basal ganglia [9]; (2) decreased tone of the internal bladder sphincter due to α1-adrenergic blockade [10]; (3) blockade of pudendal reflexes via antagonism of 5-HT2 or 3 [11]; and (4) urinary retention and subsequent overflow incontinence due to antimuscarinic properties of antipsychotics [12].

Risperidone acts as an antagonist on the 5HT2A and D2 receptors, also it has a strong blockade effect for α-1 and α-2 adrenergic receptors. Adrenergic blockade effect is suggested to urinary incontinence by decreasing the tonus of internal urethral sphincter [10]. One study showed an association between 5HT2A gene polymorphisms and polysymptomatic nocturnal enuresis [13]. The antagonist activity of aripiprazole at α1 and 5HT2A receptors on internal bladder sphincter and detrusor muscle, respectively, might have caused enuresis in this case. In addition, possible reduced dopamine transmission due to partial agonist activity of aripiprazole at D2 receptors might also cause enuresis in our case. The sedative effects of antipsychotics may lead to inability to wake up during sleep and might cause nocturnal enuresis. Because our case experienced enuresis only during the day time, and her parents reported no difficulty of the patients in waking up during risperidone or aripiprazole treatment, enuresis does not seem to be related to sedation. In contrast to one case report describing nocturnal enuresis developing in association with aripiprazole [14] and another adolescent case report of diurnal enuresis developing [8], the therapeutic effect of aripiprazole has been shown in clozapine-related enuresis [5]. Early identification of this side effect combined with early prevention may increase medication adherence. In this case, aripiprazole first caused dose-dependent enuresis in a preadolescent child, which then resolved with a mild reduction in dosage. From that perspective, this case report shows, in the light of the current literature, that two different antipsychotics are able to cause diurnal enuresis and that aripiprazole can be used in the aetiology and treatment of enuresis in a dose-dependent manner. Her Naranjo adverse drug reaction probability scale score was 8 for each drug [15].

However, the use of risperidone and aripiprazole has become widely common in treating behavioural problems (such as aggressiveness, self-injurious behaviours) associated with ASDs, thus, this case report indicate that the need to monitor the possibility of enuresis precipitated by antipsychotics is increasingly important.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**ORCID**

Hamza Ayaydin  http://orcid.org/0000-0003-4909-0070
References

[1] Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatr. 2003;42:1443–1450.

[2] Marcus RN, Owen R, Kamen L, et al. A placebo–controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatr. 2009;48:1110–1119.

[3] Harrison-Woolrych M, Skegg K, Ashton J, et al. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatr. 2011;199:140–144.

[4] Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15:869–884.

[5] Lee MJ, Kim CE. Use of aripiprazole in clozapine induced enuresis: report of two cases. J Korean Med Sci. 2010;25:333–335.

[6] Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–140.

[7] Hergüner S, Mukaddes NM. Risperidone-induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatr. 2008;32:1085–1086.

[8] Bozkurt H, Abal O. Aripiprazole-induced enuresis in a child with autistic disorder. Arch Neuropsychiatr. 2011;48:164–166.

[9] Ambrosini P. A pharmacological paradigm for urinary incontinence and enuresis. J Clin Psychopharmacol. 1984;4:247–253.

[10] Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatr. 1996;57:514–518.

[11] Kantrowitz JT, Srihari VH, Tek C. Three cases of risperidone-induced enuresis. Schizophr Res. 2006;84:174–175.

[12] Aronowitz JS, Safferman JS, Lieberman JA. Management of clozapine-induced enuresis. Am J Psychiatr. 1995;152:472a–472.

[13] Wei CC, Wan L, Lin WY, et al. Rs 6313 polymorphism in 5-hydroxytryptamine receptor 2A gene association with polysymptomatic primary nocturnal enuresis. J Clin Lab Anal. 2010;24:371–375.

[14] Karakurt MN, Süren S. Desmopressin use in the treatment of aripiprazole-induced nocturnal enuresis in a child diagnosed with autistic disorder. J Child Adolesc Psychopharmacol. 2015;25:518–519.

[15] Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo adverse drug reactions probability scale. Psychiatr Clin Psychopharmacol. 2017;27:205–206.